Updates

Texas Children’s Faculty Secure $3.2M in Recent Research Grants

Health Briefs

Texas Children’s Cancer & Hematology Center is proud to celebrate faculty who have recently secured a total of over $3.2M in competitive research grants supporting innovative projects across cancer biology, immunotherapy, disease monitoring, and cancer susceptibility. These awards will advance new strategies to improve outcomes for children and adolescents with cancer and serious blood disorders.

The following Principal Investigators and projects were recently awarded funding (pictured above, left to right by row):

  • Carl E. Allen, MD, PhD 
    Curing Pediatric Langerhans Cell Histiocytosis: Testing Synergy of Chemotherapy and MAPK Inhibition 
    Funding Agency: Pediatric Cancer Research Foundation
  • Austin L. Brown, PhD, MPH 
    Exploring the role of immune dysregulation on Hodgkin lymphoma susceptibility 
    Funding Agency: Jeffrey Pride Foundation
  • Lisa S. Kahalley, PhD 
    Radiation Dose-Volume Associations with Neurocognitive Change in Pediatric Brain Tumor Patients Treated with Proton vs. Photon Radiotherapy 
    Funding Agency: Cancer Prevention & Research Institute of Texas (CPRIT)
  • Bilal A. Omer, MD 
    Toward Durable Remissions: Gene-Edited GD2-CAR T Cells to Overcome Resistance in Pediatric Brain Tumors 
    Funding Agency: The Faris Foundation
  • Debananda Pati, PhD 
    Advancing P27600: A Novel Plant-Derived Compound for Treating Ewing Sarcoma 
    Funding Agency: Kate Amato Foundation
  • Michele S. Redell, MD, PhD 
    Updated Disease Monitoring & Treatment to Enhance Pediatric AML Outcomes 
    Funding Agency: Cannonball Kids’ Cancer Foundation
  • David H. Steffin, MD and Helen E. Heslop, MD, DSc (Hon) (not pictured) 
    Cancer Adoptive Cellular Therapy (CAN-ACT); Administrative Supplement to Specialized Programs of Research Excellence (SPORE) in Lymphoma (P50) 
    Funding Agency: National Institutes of Health (NIH)
  • Gengwen Tian, MD, PhD 
    Enhancing GD2-CAR NKT Anti-Tumor Efficacy against Neuroblastoma through Targeting BLIMP1 
    Funding Agency: The Andrew McDonough B+ Foundation
  • Andrew A. Wahba, MD 
    Early Career Award Program: Advancing Pediatric Cancer Immunotherapy with CAR-NKT Cells 
    Funding Agency: Thrasher Research Fund

We thank these funding agencies and our dedicated faculty for their commitment to advancing care and research for young patients. Their work and collaboration allow Texas Children’s to continue its mission to lead in pediatric cancer and hematology innovation.

Learn more about previous research grants here: https://www.texaschildrens.org/content/awards/recent-grant-funding-texas-childrens-cancer-hematology-center